Current diagnosis and treatment of CIN II


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

This review article is aimed at raising the awareness of obstetrician-gynecologists about the appropriateness of conservative management of patients aged under 25, primary prevention of HPV-associated cervical diseases and cervical cancer, and the possibility of reducing the risk of recurrence after curative treatment. The article summarizes research evidence from relevant international and domestic scientific literature available at PubMed and published over the past 10 years. The authors analyze current literature on the conservative management of young patients with cervical intraepithelial neoplasia II (CIN II) and present data on the prevalence, diagnosis, and features of the course of CIN II in women aged under 25, and the role of human papillomavirus in cancer development. The review addresses the importance of primary prevention of cervical cancer, the feasibility of conservative treatment of young patients with CIN II, and the possibility of reducing the risk of recurrence after curative treatment. This review article should be helpful for obstetrician-gynecologists in increasing their knowledge on the primary prevention of cervical cancer, and strategy for conservative management of young patients with CIN II to preserve their reproductive potential.

Full Text

Restricted Access

About the authors

V. I Krasnopol’skii

Moscow Regional Research Institute of Obstetrics and Gynecology of Minzdrav of Moscow Region

N. V Zarochentseva

Moscow Regional Research Institute of Obstetrics and Gynecology of Minzdrav of Moscow Region

Email: ninazarii@mail.ru

L. A Ashrafyan

V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology of Minzdrav of Russia

V. I Kiselev

V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology of Minzdrav of Russia

L. K Dzhidzhikhiya

Moscow Regional Research Institute of Obstetrics and Gynecology of Minzdrav of Moscow Region

Email: lel33ii@yandex.ru

I. I Baranov

V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology of Minzdrav of Russia

M. G Dzhavakhishvili

Moscow Regional Research Institute of Obstetrics and Gynecology of Minzdrav of Moscow Region

References

  1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global Glo bal cancer statistics 2018: GLOBOCAN estimates of incidence and mortality w orldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018; 68(6): 394-424. https://dx.doi.org/10.3322/caac.21492.
  2. International Classification of Diseases 11th Revision. Available at: https:// icd. who.int
  3. Kurman R.J., Carcangiu M.L., Herrington C.S., Young R.H. WHO Classification of tumours of female reproductive organs. Lyon: IARC; 2014.
  4. Wright T.C. Jr, Massad L.S., Dunton C.J., Spitzer M., Wilkinson E.J., Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Lower Genit. Tract Dis. 2007; 11(4): 201-22. https://dx.doi. org/10.1097/LGT.0b013e3181585870.
  5. De Sanjose S., Quint W.G., Alemany L., Geraets D.T., Klaustermeier J.E., Lloveras B. et al.; Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010; 11(11): 1048-56. https://dx.doi.org/10.1016/S1470-2045(10)70230-8.
  6. Oakeshott P., Aghaizu A., Reid F., Howell-Jones R., Hay P.E., Sadiq S.T. et al. Frequency and risk factors for prevalent, incident, and persistent genital carcinogenic human papillomavirus infection in sexually active women: community based cohort study. BMJ 2012; 344: e4168. https://dx.doi.org/10.1136/bmj.e4168.
  7. Madeleine M.M., Anttila T., Schwartz S.M., Saikku P., Leinonen M., Carter J.J. et al. Risk of cervical cancer associated with Chlamydia trachomatis antibodies by histology, HPV type and HPV cofactors. Int. J. Cancer. 2007; 120(3): 650-5. https://dx.doi.org/10.1002/ijc.22325.
  8. Smith J.S., Herrero R., Bosetti C., MunozN., Bosch F.X., Eluf-Neto J. et al. Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J. Natl. Cancer Inst. 2002; 94(21): 1604-13. https://dx.doi. org/10.1093/jnci/94.21.1604.
  9. Савельева Г.М., Сухих Г.Т., Серов В.Н., Радзинский В.Е., Манухин И.Б., ред. Гинекология. Национальное руководство. М.: ГЭОТАР-Медиа; 2017. 989 с. [Savel’eva G.M., Sukhikh G.T., Serov V.N., Radzinskii V.E., Manukhin I.B., eds. Ginekologiya. Natsional’noe rukovodstvo. Moscow: GEOTAR-Media; 2017. 989 p. (in Russian)].
  10. Padmini C.P., Indira N., Chaitra R., Das P., Girish B.C., Nanda K.M. Cytological and colposcopic evaluation of unhealthy cervix. J. Evid. Based Med. Healthc. 2015; 2: 6920-7. https://dx.doi.org/10.18410/jebmh/2015/925.
  11. Schmidt D. Modern biomarkers for precancerous lesions of the uterine cervix: Histological-cytological correlation and use. Pathologe. 2016; 37(6): 534-41. https://dx.doi.org/10.1007/s00292-016-0231-3.
  12. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 99: management of abnormal cervical cytology and histology. Obstet. Gynecol. 2008; 112(6): 1419-44. https://dx.doi.org/10.1097/ AOG.0b013e318192497c.
  13. Краснопольский В.И., Короленкова Л.И., Зароченцева Н.В., Жордания К.И., Щукина Н.А. Облигатные формы предрака и инвазивный рак шейки матки. Руководство для врачей. Краснопольский В.И., ред. М.: СИМК; 2017. 160 с. [Krasnopol’skii V.I., Korolenkova L.I., Zarochentseva N.V., Zhordaniya K.I., Shchukina N.A. Obligatnye formy predraka i invazivnyi rak sheiki matki. Rukovodstvo dlya vrachei. Krasnopol’skii V.I., ed. Moscow: SIMK; 2017. 160 p. (in Russian)].
  14. Schiffman M., Solomon D. Findings to date from the ASCUS-LSIL Triage Study (ALTS). Arch. Pathol. Lab. Med. 2003; 127(8): 946-9. https://dx.doi.org/10.1043/1543-2165(2003)127<946:FTDFTA>2.0.CO;2.
  15. Klaes R., Friedrich T., Spitkovsky D., Ridder R., Rudy W., Petry U. et al. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int. J. Cancer. 2001; 92(2): 276-84. https://dx.doi.org/10.1002/ijc.1174.
  16. Saslow D., Solomon D., Lawson H.W., Killackey M., Kulasingam S.L., Cain J. et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am. J. Clin. Pathol. 2012; 137(4): 516-42. https://dx.doi.org/10.1309/AJCPTGD94EVRSJCG.
  17. Miyamoto S., Hasegawa J., Morioka M., Hirota Y., Kushima M., Sekizawa A. The association between p16 and Ki-67 immunohistostaining and the progression of cervical intraepithelial neoplasia grade 2. Int. J. Gynaecol. Obstet. 2016; 134(1): 45-8. https://dx.doi.org/10.1016/ j.ijgo.2015.12.005.
  18. Demarco M., Lorey T.S., Fetterman B., Cheung L.C., Guido R.S., Wentzensen N. et al. Risks of CIN 2+, CIN 3+, and cancer by cytology and human papillomavirus status: the foundation of risk-based cervical screening guidelines. J. Low Genit. Tract Dis. 2017; 21(4): 261-7. https://dx.doi.org/10.1097/ LGT.0000000000000343.
  19. NHSCSP Guidelines no.20 (3rd edition). Home/Medical Professionals/ NHSCSP Guidelines. Colposcopy and Programme Management: Guidelines for the NHS Cervical Screening Programme Published March 2016. Available at: https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=370275
  20. Bentley J. Colposcopic management of abnormal cervical cytology and histology. J. Obstet. Gynaecol. Can. 2012; 34(12): 1188-202. https://dx.doi.org/10.1016/ S1701-2163(16)35468-8.
  21. Moscicki A.B., Ma Y., Wibbelsman C., Darragh T.M., Powers A., Farhat S., Shiboski S. Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women. Obstet. Gynecol. 2010; 116(6): 1373-80. https://dx.doi.org/10.1097/AOG.0b013e3181fe777f.
  22. McAllum B., Sykes P.H.H., Sadler L., Macnab H., Simcock B.J., Mekhail A.K. Is the treatment of CIN 2 always necessary in women under 25 years old? Am. J. Obstet. Gynecol. 2011; 205(5): 478. e1-7. https://dx.doi.org/10.1016/j. ajog.2011.06.069.
  23. Loopik D.L., Bekkers R.L.M., Massuger L.F.A.G., Melchers W.J.G., Siebers A.G., Bentley J. Justifying conservative management of CIN2 in women younger than 25 years - A population-based study. Gynecol. Oncol. 2019; 152(1): 82-6. https://dx.doi.org/10.1016/j.ygyno.2018.10.038.
  24. Tainio K., Athanasiou A., Tikkinen K.A.O., Aaltonen R., Cardenas J., Hernandes. et al. Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis. BMJ. 2018; 360: k499. https://dx.doi.org/10.1136/bmj.k499.
  25. Sasieni P., Castanon J., Parkin D.M. How many cancers are prevented by treatment of screen-detected disease in young women? Int. J. Cancer. 2009; 124: 461-4. https://dx.doi.org/10.1002/ijc.23922.
  26. Castle P.E., Schiffman M., Wheeler C.M., Solomon D. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet. Gynecol. 2009; 113(1): 18-25. https://dx.doi.org/10.1097/AOG.0b013e31818f5008.
  27. Discacciati M.G., de Souza C.A., d’Otavianno M.G., Angelo-Andrade L.A., Westin M.C., Rabelo-Santos S.H., Zeferino L.C. Outcome of expectant management of cervical intraepithelial neoplasia grade 2 in women followed for 12 months. Eur. J. Obstet. Gynecol. Reprod. Biol. 2011; 155(2): 204-8. https:// dx.doi.org/10.1016/j.ejogrb.2010.12.002.
  28. Fuchs K., Weitzen S., Wu L., Phipps M.G., Boardman L.A. Management of cervical intraepithelial neoplasia 2 in adolescent and young women. J. Pediatr. Adolesc. Gynecol. 2007; 20(5): 269-74. https://dx.doi.org/10.1016/j. jpag.2007.04.012.
  29. Moore K., Cofer A., Elliot L., Lanneau G., Walker J., Gold M.A. Adolescent cervical dysplasia: histologic evaluation, treatment, and outcomes. Am. J. Obstet. Gynecol. 2007; 197(2): 141. e1-6. https://dx.doi.org/10.1016/ j.ajog.2007.03.029.
  30. Guedes A.C., Zeferino L.C., Syrjanen K.J., Brenna S.M.F. Short-term outcome of cervical intraepithelial neoplasia grade 2: considerations for management strategies and reproducibility of diagnosis. Anticancer Res. 2010; 30(6): 2319-23.
  31. Kyrgiou M., Mitra A., Arbyn M., Stasinou S.M., Martin-Hirsch P., Bennett P., Paraskevaidis E. Fertility and early pregnancy outcomes after treatment for cervical intraepithelial neoplasia: systematic review and meta-analysis. BMJ. 2014; 349: g6192. https://dx.doi.org/10.1136/bmj.g6192.
  32. Wilkinson T.M., Sykes P.H., Simcock B., Petrich S. Recurrence of high-grade cervical abnormalities following conservative management of cervical intraepithelial neoplasia grade 2. Am. J. Obstet. Gynecol. 2015; 212(6): 769. e1-7. https://dx.doi.org/10.1016/j.ajog.2015.01.010.
  33. Castanon A., Brocklehurst P., Evans H., Peebles D., Singh N., Walker P. et al. Risk of preterm birth after treatment for cervical intraepithelial neoplasia among women attending colposcopy in England: retrospectiveprospective cohort study. BMJ. 2012; 345: e5174. https://dx.doi.org/10.1136/ bmj.e5174.
  34. Janevic T., Stein C.R., Savitz D.A., Kaufman J.S., Mason S.M., Herring A.H. Neighborhood deprivation and adverse birth outcomes among diverse ethnic groups. Ann. Epidemiol. 2010; 20(6): 445-51. https://dx.doi.org/10.1016/ j.annepidem.2010.02.010.
  35. Perkins R.B., Jorgensen J.R., McCoy M.E., BakS.M., Battaglia T.A., Freund K.M. Adherence to conservative management recommendations for abnormal PAP test results in adolescents. Obstet. Gynecol. 2012; 119(6): 1157-63. https://dx.doi.org/10.1097/AOG.0b013e31824e9f2f.
  36. Massad L.S., Einstein M.H., Huh W.K., Katki H.A., Kinney W.K., Schiffman M. et al. 2012 updated consensus guide- lines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet. Gynecol. 2013; 121(4): 829-46. https://dx.doi.org/10.1097/AOG.0b013e3182883a34.
  37. Paraskevaidis E., Arbyn M., Sotiriadis A., Diakomanolis E., Martin-Hirsch P., Koliopoulos G. et al. The role of DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature. Cancer Treat. Rev. 2004; 30(2): 205-11. https://dx.doi.org/10.1016/j.ctrv.2003.07.008.
  38. Клинические рекомендации «Доброкачественные и предраковые заболевания шейки матки с позиции профилактики рака». М.; 2017. 55 с.
  39. Zhu J., Li Y., Guan C., Chen Z. Anti-proliferative and pro-apoptotic effects of 3,3’- diindolylmethane in human cervical cancer cells. Oncol. Rep. 2012; 28(3): 1063-8. https://dx.doi.org/10.3892/or.2012.1877.
  40. Sales K.J., Katz A.A. Inflammatory pathways in cervical cancer -the UCT contribution. South Afr. Med. J. 2012; 102(6): 493-6. https://dx.doi.org/10.7196/samj.5532.
  41. Wu T.Y., Khor T.O., Su Z.Y., Saw C.L., Shu L., Cheung K.L. et al. Epigenetic modifications of Nrf2 by 3,3’-diindolylmethane in vitro in TRAMP C1 cell line and in vivo TRAMP prostate tumors. AAPS J. 2013; 15(3): 864-74. https:// dx.doi.org/10.1208/s12248-013-9493-3.
  42. Сухих Г.Т., Ашрафян Л.А., Киселев В.И., Аполихина И.А., Мальцева Л.И., Сутурина Л.В., Селиванов С.П., Леонидова Т.Н., Цхай В.Б., Радзинский В.Е., Ордиянц И.М., Бебнева Т.Н., Евтушенко И.Д., Удут В.В., Кулагина Н.В., Баранов А.Н., Хасанов Р.Ш., Гурьева В.А., Шамина И.В., Карахалис Л.Ю., Муйжнек Е.Л. Исследование эффективности и безопасности препарата на основе дииндол ил метана у пациенток с цервикальной интраэпителиальной неоплазией (CIN 1-2). Акушерство и гинекология. 2018; 9: 991-8. https://dx.doi.org/10.18565/aig.2018.9.91-98.
  43. Киселев В.И., Ашрафян Л.А., Друх В.М., Муйжнек Е.Л., Кузнецов И.Н., Пчелинцева О.И., Андрианова Е.А., Барановский П.М. Клиническое исследование по изучению эффективности суппозиториев «Цервикон-ДИМ» при лечении цервикальной интраэпителиальной неоплазии легкой и средней степени. Вестник Российского научного центра рентгенорадиологии Минздрава России. 2014; 14-3: 6.
  44. Ashrafian L., Sukhikh G., Kiselev V., Paltsev M., Drukh V., Kuznetsov I., Muyzhnek E., Apolikhina I., Andrianova E. Double-blind randomized placebocontrolled multicenter clinical trial (phase IIa) on diindolylmethane’s efficacy and safety in the treatment of CIN: implications for cervical cancer prevention. EPMA J. 2015 Dec 21;6:25. https://dx.doi.org/10.1186/s13167-015-0048-9.
  45. Food and Drug Administration (FDA). Vaccines, blood and biologics. FDA,; 2017. Available at: https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ ApprovedProducts
  46. Drolet M, Benard E., Boily M.C., AH H., Baandrup L., Bauer H. et al. Populationlevel impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect. Dis. 2015; 15(5): 565-80. https://dx.doi.org/10.1016/S1473-3099(14)71073-4.
  47. Joura E.A., Garland S.M., Paavonen J., Ferris D.G., Perez G., Ault K.A. et al. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ. 2012; 344: e1401. https://dx.doi.org/10.1136/bmj.e1401.
  48. Kang W.D., Choi H.S., Kim S.M. Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision pro cedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)? Gynecol. Oncol. 2013; 130(2): 264-8. https://dx.doi.org/10.1016/ j.ygyno.2013.04.050.
  49. Ghelardi A., Parazzini F., Martella F., Pieralli A., Bay P., Tonetti A. et al. SPERANZA project: HPV vaccination after treatment for CIN2. Gynecol. Oncol. 2018; 151(2): 229-34. https://dx.doi.org/10.1016/j.ygyno.2018.08.033.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies